Ratings Moves: ING,...
Health Care: Drugs
ZymoGenetics Inc. (ZGEN: NASDAQ)
$9.76 0.01 | 0.10%
10/12/10 - 04:00 PM ET
222.99K / 2.47M
Vol / Avg. Vol:9.74 / 9.75
Open / Prev. Close:9.74 - 9.76
Today's Range:3.70 - 9.79
52 Wk Range:52.74%
Performance YTD:TheStreet Rating:
Portfolios with ZGEN
- Portfolio NameUser Type
- UserASCO 2010
- UserMy Portfolio- warning high...
- UserWilliam T Blanchard - Medical
- Userwallacee Portfolio 1
- UserASCO 2009 Nymph's Watch List.
- Usersil Portfolio 1
- UserPART 6 JPMorgan 27th Annual...
- UserRooney McFaddy Portfolio 1
- UserRRR007
- UserMPM
Latest ZGEN Headlines from TheStreet
- 52-Week Stock Highs: Oracle, Qwest 09.17.10 | 02:09 pm
- ZymoGenetics, Mitcham: Volume Movers 09.08.10 | 08:09 am
- Business Highlights 09.07.10 | 06:09 pm
- Business Highlights 09.07.10 | 06:09 pm
- Bristol-Myers Pays Up for ZymoGenetics 09.07.10 | 05:09 pm
- ZymoGenetics Inc Q2 2010 Earnings Call Transcript 08.08.10 | 12:08 pm
- Javelin Pharmaceuticals, FuelCell Energy: Midday Volume Plays 06.03.10 | 01:06 pm
- ZymoGenetics, Inc. Q1 2010 Earnings Call Transcript 05.04.10 | 08:05 pm
- Pacific Ethanol, ZymoGenetics: Early Volume Plays 01.07.10 | 07:01 am
- ZymoGenetics Shares Fall On Regulatory Delay 12.15.09 | 01:12 pm
Press Releases for ZGEN
- Bristol-Myers Squibb Completes Acquisition Of ZymoGenetics, Inc. - Business Wire 10.12.10 | 04:10 pm
- Bristol-Myers Squibb Completes Tender Offer For ZymoGenetics, Inc. With 94.9% Of Shares Tendered - Business Wire 10.08.10 | 08:10 am
- ZymoGenetics And Bristol-Myers Squibb To Present PEG-Interferon Lambda Phase 2a Interim Clinical Trial Results At AASLD 2010 - Business Wire 10.01.10 | 01:10 pm
- ZymoGenetics And Bristol-Myers Squibb To Present PEG-Interferon Lambda Phase 2a Interim Clinical Trial Results At AASLD 2010 - Business Wire 10.01.10 | 01:10 pm
- ZymoGenetics Reports Favorable Survival Data From IL-21 Phase 2a Clinical Trial In Melanoma - Business Wire 09.29.10 | 06:09 am
- Bristol-Myers Squibb Announces Expiration Of Hart-Scott-Rodino Waiting Period For Acquisition Of ZymoGenetics, Inc. - Business Wire 09.28.10 | 07:09 am
- Law Offices Of Howard G. Smith Announces Investigation On Behalf Of Shareholders Of ZymoGenetics, Inc. - Business Wire 09.14.10 | 08:09 pm
- The Law Office Of Abe Shainberg Announces An Investigation Into The Possible Breaches Of Fiduciary Duty By The Board Of ZymoGenetics, Inc. In Connection With The Sale Of The Company To Bristol-Myers Squibb Co. - ZGEN - Business Wire 09.13.10 | 03:09 pm
- Bristol-Myers Squibb Begins Tender Offer To Acquire ZymoGenetics, Inc. - Business Wire 09.10.10 | 07:09 am
- Faruqi & Faruqi, LLP Announces Investigation Related To The Acquisition Of ZymoGenetics, Inc. – ZGEN - Business Wire 09.08.10 | 04:09 pm
Partner Headlines for ZGEN
- Bristol-Myers Squibb Completes Acquisition of ZymoGenetics, Inc. at $9.75 per Share - Benzinga 10.12.10 | 04:10 pm
- Bristol Myers at Neutral - Analyst Blog - Zacks 10.04.10 | 06:10 pm
- Achillion's Pipeline Progresses - Analyst Blog - Zacks 10.01.10 | 06:10 pm
- UPDATE 1-ZymoGenetics' skin cancer drug shows promise in study - Reuters 09.29.10 | 07:09 am
- Big Pharma Looks to Biotech for Innovation - Seeking Alpha 09.12.10 | 08:09 am
- Zacks Analyst Blog Highlights: Bristol-Myers Squibb, ZymoGenetics, Family Dollar Stores, Wal-Mart Stores and Dollar General Corporation - Press Releases - Zacks 09.09.10 | 08:09 am
- BMY to Acquire ZymoGenetics - Analyst Blog - Zacks 09.08.10 | 04:09 pm
- Wednesday Options Update: BAC, XRT, ZMH, GMCR, COF, YHOO, ZGEN, NYT - Seeking Alpha 09.08.10 | 03:09 pm
- ZymoGenetics Shares Surge on Bristol-Myers Squibb Buyout - Fox Business 09.08.10 | 01:09 pm
- Company News for September 8, 2010 - Corporate Summary - Zacks 09.08.10 | 10:09 am
